🎉 M&A multiples are live!
Check it out!

Grace Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Grace Therapeutics and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Grace Therapeutics Overview

About Grace Therapeutics

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.


Founded

2002

HQ

United States of America
Employees

7

Financials

LTM Revenue n/a

LTM EBITDA -$16.7M

EV

$6.4M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Grace Therapeutics Financials

Grace Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$16.7M.

In the most recent fiscal year, Grace Therapeutics achieved revenue of n/a and an EBITDA of -$11.3M.

Grace Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Grace Therapeutics valuation multiples based on analyst estimates

Grace Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$18.1M -$11.3M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$9.8M -$42.4M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Grace Therapeutics Stock Performance

As of April 15, 2025, Grace Therapeutics's stock price is $2.

Grace Therapeutics has current market cap of $29.4M, and EV of $6.4M.

See Grace Therapeutics trading valuation data

Grace Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$6.4M $29.4M XXX XXX XXX XXX $-1.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Grace Therapeutics Valuation Multiples

As of April 15, 2025, Grace Therapeutics has market cap of $29.4M and EV of $6.4M.

Grace Therapeutics's trades at n/a LTM EV/Revenue multiple, and -0.4x LTM EBITDA.

Analysts estimate Grace Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Grace Therapeutics and 10K+ public comps

Grace Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $6.4M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.4x XXX XXX XXX
P/E -2.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Grace Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Grace Therapeutics Valuation Multiples

Grace Therapeutics's NTM/LTM revenue growth is Infinity%

Grace Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.6M for the same period.

Over next 12 months, Grace Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Grace Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Grace Therapeutics and other 10K+ public comps

Grace Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -37% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Grace Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Grace Therapeutics M&A and Investment Activity

Grace Therapeutics acquired  XXX companies to date.

Last acquisition by Grace Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Grace Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Grace Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Grace Therapeutics

When was Grace Therapeutics founded? Grace Therapeutics was founded in 2002.
Where is Grace Therapeutics headquartered? Grace Therapeutics is headquartered in United States of America.
How many employees does Grace Therapeutics have? As of today, Grace Therapeutics has 7 employees.
Who is the CEO of Grace Therapeutics? Grace Therapeutics's CEO is Mr. Prashant Kohli.
Is Grace Therapeutics publicy listed? Yes, Grace Therapeutics is a public company listed on NAS.
What is the stock symbol of Grace Therapeutics? Grace Therapeutics trades under GRCE ticker.
When did Grace Therapeutics go public? Grace Therapeutics went public in 2011.
Who are competitors of Grace Therapeutics? Similar companies to Grace Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Grace Therapeutics? Grace Therapeutics's current market cap is $29.4M
What is the current EBITDA of Grace Therapeutics? Grace Therapeutics's last 12-month EBITDA is -$16.7M.
What is the current EV/EBITDA multiple of Grace Therapeutics? Current EBITDA multiple of Grace Therapeutics is -0.4x.
Is Grace Therapeutics profitable? Yes, Grace Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.